The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
Open accessAbstract
Summary: Background and objectives: The principle defect in dense deposit disease and C3 glomerulonephritis is hyperactivity of the alternative complement pathway. Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex, may prove beneficial. Design, setting, participants, & measurements: In this open-label, proof of concept efficacy and safety study, six subjects with dense deposit disease or C3 glomerulonephritis were treated with eculizumab every other week for 1 year. All had proteinuria >1 g/d and/or AKI at enrollment. Subjects underwent biopsy before enrollment and repeat biopsy at the 1-year mark. Results: The subjects included three patients with dense deposit disease (including one patient with recurrent dense deposit disease in allograft) and three patients with C3 glomerulonephritis (including two patients with recurrent C3 glomerulonephritis in allograft). Genetic and complement function testing revealed a mutation in CFH and MCP in one subject each, C3 nephritic factor in three subjects, and elevated levels of serum membrane attack complex in three subjects. After 12 months, two subjects showed significantly reduced serum creatinine, one subject achieved marked reduction in proteinuria, and one subject had stable laboratory parameters but histopathologic improvements. Elevated serum membrane attack complex levels normalized on therapy and paralleled improvements in creatinine and proteinuria. Conclusions: Clinical and histopathologic data suggest a response to eculizumab in some but not all subjects with dense deposit disease and C3 glomerulonephritis. Elevation of serum membrane attack complex before treatment may predict response. Additional research is needed to define the subgroup of dense deposit disease/C3 glomerulonephritis patients in whom eculizumab therapy can be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update
Appel, G. B., Cook, H. T., Hageman, G., Jennette, J. C., Kashgarian, M., Kirschfink, M., Lambris, J. D., Lanning, L., Lutz, H. U., Meri, S., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010078 · Cited by 380
Self-citationC3 glomerulopathy: a new classification
Fakhouri, F., Frémeaux-Bacchi, V., Noël, L.-H., Cook, H. T., & Pickering, M. C. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.85 · Cited by 363
Gale, D. P., de Jorge, E. G., Cook, H. T., Martinez-Barricarte, R., Hadjisavvas, A., McLean, A. G., Pusey, C. D., Pierides, A., Kyriacou, K., Athanasiou, Y., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60670-8 · Cited by 327
Maga, T. K., Nishimura, C. J., Weaver, A. E., Frees, K. L., & Smith, R. J. H. (2010) · Human Mutation · doi:10.1002/humu.21256 · Cited by 308
Self-citationServais, A., Frémeaux-Bacchi, V., Lequintrec, M., Salomon, R., Blouin, J., Knebelmann, B., Grünfeld, J.-P., Lesavre, P., Noël, L.-H., & Fakhouri, F. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045328 · Cited by 291
Martínez-Barricarte, R., Heurich, M., Valdes-Cañedo, F., Vazquez-Martul, E., Torreira, E., Montes, T., Tortajada, A., Pinto, S., Lopez-Trascasa, M., Morgan, B. P., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43343 · Cited by 222
Abrera-Abeleda, M. A., Nishimura, C., Smith, J. L. H., Sethi, S., McRae, J. L., Murphy, B. F., Silvestri, G., Skerka, C., Józsi, M., Zipfel, P. F., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2005.038315 · Cited by 216
Self-citationMembranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion
Sethi, S., Nester, C. M., & Smith, R. J. H. (2012) · Kidney International · doi:10.1038/ki.2011.399 · Cited by 212
Self-citationCauses of Alternative Pathway Dysregulation in Dense Deposit Disease
Zhang, Y., Meyer, N. C., Wang, K., Nishimura, C., Frees, K., Jones, M., Katz, L. M., Sethi, S., & Smith, R. J. H. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07900811 · Cited by 188
Self-citationEculizumab for paroxysmal nocturnal haemoglobinuria
Parker, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60001-5 · Cited by 164
Pathology after Eculizumab in Dense Deposit Disease and C3 GN
Herlitz, L., Bomback, A. S., Markowitz, G. S., Stokes, M. B., Smith, R. N., Colvin, R. B., Appel, G. B., & D’Agati, V. D. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121186 · Cited by 155
Self-citationProliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement
Sethi, S. M., Fervenza, F. C., Zhang, Y., Nasr, S. H., Leung, N., Vrana, J. A., Cramer, C. H., Nester, C., & Smith, R. J. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07110810 · Cited by 146
Self-citationC3 deposition glomerulopathy due to a functional Factor H defect
Habbig, S., Mihatsch, M. J., Heinen, S., Beck, B. B., Emmel, M., Skerka, C., Kirschfink, M., Höppe, B., Zipfel, P. F., & Licht, C. P. B. (2008) · Kidney International · doi:10.1038/ki.2008.354 · Cited by 90
Extensive Drusen in Type I Membranoproliferative Glomerulonephritis
Han, D. P. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.38 · Cited by 17
Cited by
Goodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citationC3 glomerulopathy: consensus report
Pickering, M. C., D'Agati, V. D., Nester, C. M., Smith, R. J., Haas, M., Appel, G. B., Alpers, C. E., Bajema, I. M., Bedrosian, C., Braun, M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.377 · Cited by 653
Self-citationUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
C3 glomerulopathy — understanding a rare complement-driven renal disease
Smith, R. J. H., Appel, G. B., Blom, A. M., Cook, H. T., D’Agati, V. D., Fakhouri, F., Fremeaux-Bacchi, V., Józsi, M., Kavanagh, D., Lambris, J. D., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0107-2 · Cited by 409
Self-citationThe renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Metadata
- Authors
- Bomback, A. S., Smith, R. J., Barile, G. R., Zhang, Y., Heher, E. C., Herlitz, L., Stokes, M. B., Markowitz, G. S., D’Agati, V. D., Canetta, P. A., Radhakrishnan, J., & Appel, G. B.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2012-05
- Volume
- 7
- Issue
- 5
- Pages
- 748-756
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2107516496
- Cited by
- 366
- References
- 14
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.